Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: Study design and rationale

David Charles, Christopher Tolleson, Thomas L. Davis, Chandler E. Gill, Anna L. Molinari, Mark J. Bliton, Michael G. Tramontana, Ronald M. Salomon, Chris Kao, Lily Wang, Peter Hedera, Fenna T. Phibbs, Joseph S. Neimat, Peter E. Konrad

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Deep brain stimulation provides significant symptomatic benefit for people with advanced Parkinson's disease whose symptoms are no longer adequately controlled with medication. Preliminary evidence suggests that subthalamic nucleus stimulation may also be efficacious in early Parkinson's disease, and results of animal studies suggest that it may spare dopaminergic neurons in the substantia nigra. Objective: We report the methodology and design of a novel Phase I clinical trial testing the safety and tolerability of deep brain stimulation in early Parkinson's disease and discuss previous failed attempts at neuroprotection. Methods: We recently conducted a prospective, randomized, parallel-group, single-blind pilot clinical trial of deep brain stimulation in early Parkinson's disease. Subjects were randomized to receive either optimal drug therapy or deep brain stimulation plus optimal drug therapy. Follow-up visits occurred every six months for a period of two years and included week-long therapy washouts. Results: Thirty subjects with Hoehn & Yahr Stage II idiopathic Parkinson's disease were enrolled over a period of 32 months. Twenty-nine subjects completed all follow-up visits; one patient in the optimal drug therapy group withdrew from the study after baseline. Baseline characteristics for all thirty patients were not significantly different. Conclusions: This study demonstrates that it is possible to recruit and retain subjects in a clinical trial testing deep brain stimulation in early Parkinson's disease. The results of this trial will be used to support the design of a Phase III, multicenter trial investigating the efficacy of deep brain stimulation in early Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)215-223
Number of pages9
JournalJournal of Parkinson's Disease
Volume2
Issue number3
DOIs
StatePublished - Oct 22 2012
Externally publishedYes

Fingerprint

Subthalamic Nucleus
Deep Brain Stimulation
Parkinson Disease
Drug Therapy
Clinical Trials
Clinical Trials, Phase I
Dopaminergic Neurons
Substantia Nigra
Multicenter Studies
Safety

Keywords

  • deep brain stimulation
  • Parkinson's disease
  • research design
  • subthalamic nucleus

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease : Study design and rationale. / Charles, David; Tolleson, Christopher; Davis, Thomas L.; Gill, Chandler E.; Molinari, Anna L.; Bliton, Mark J.; Tramontana, Michael G.; Salomon, Ronald M.; Kao, Chris; Wang, Lily; Hedera, Peter; Phibbs, Fenna T.; Neimat, Joseph S.; Konrad, Peter E.

In: Journal of Parkinson's Disease, Vol. 2, No. 3, 22.10.2012, p. 215-223.

Research output: Contribution to journalArticle

Charles, D, Tolleson, C, Davis, TL, Gill, CE, Molinari, AL, Bliton, MJ, Tramontana, MG, Salomon, RM, Kao, C, Wang, L, Hedera, P, Phibbs, FT, Neimat, JS & Konrad, PE 2012, 'Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: Study design and rationale', Journal of Parkinson's Disease, vol. 2, no. 3, pp. 215-223. https://doi.org/10.3233/JPD-2012-012095
Charles, David ; Tolleson, Christopher ; Davis, Thomas L. ; Gill, Chandler E. ; Molinari, Anna L. ; Bliton, Mark J. ; Tramontana, Michael G. ; Salomon, Ronald M. ; Kao, Chris ; Wang, Lily ; Hedera, Peter ; Phibbs, Fenna T. ; Neimat, Joseph S. ; Konrad, Peter E. / Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease : Study design and rationale. In: Journal of Parkinson's Disease. 2012 ; Vol. 2, No. 3. pp. 215-223.
@article{fa9b93d9be554858be7d934b43f7ef2d,
title = "Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: Study design and rationale",
abstract = "Background: Deep brain stimulation provides significant symptomatic benefit for people with advanced Parkinson's disease whose symptoms are no longer adequately controlled with medication. Preliminary evidence suggests that subthalamic nucleus stimulation may also be efficacious in early Parkinson's disease, and results of animal studies suggest that it may spare dopaminergic neurons in the substantia nigra. Objective: We report the methodology and design of a novel Phase I clinical trial testing the safety and tolerability of deep brain stimulation in early Parkinson's disease and discuss previous failed attempts at neuroprotection. Methods: We recently conducted a prospective, randomized, parallel-group, single-blind pilot clinical trial of deep brain stimulation in early Parkinson's disease. Subjects were randomized to receive either optimal drug therapy or deep brain stimulation plus optimal drug therapy. Follow-up visits occurred every six months for a period of two years and included week-long therapy washouts. Results: Thirty subjects with Hoehn & Yahr Stage II idiopathic Parkinson's disease were enrolled over a period of 32 months. Twenty-nine subjects completed all follow-up visits; one patient in the optimal drug therapy group withdrew from the study after baseline. Baseline characteristics for all thirty patients were not significantly different. Conclusions: This study demonstrates that it is possible to recruit and retain subjects in a clinical trial testing deep brain stimulation in early Parkinson's disease. The results of this trial will be used to support the design of a Phase III, multicenter trial investigating the efficacy of deep brain stimulation in early Parkinson's disease.",
keywords = "deep brain stimulation, Parkinson's disease, research design, subthalamic nucleus",
author = "David Charles and Christopher Tolleson and Davis, {Thomas L.} and Gill, {Chandler E.} and Molinari, {Anna L.} and Bliton, {Mark J.} and Tramontana, {Michael G.} and Salomon, {Ronald M.} and Chris Kao and Lily Wang and Peter Hedera and Phibbs, {Fenna T.} and Neimat, {Joseph S.} and Konrad, {Peter E.}",
year = "2012",
month = "10",
day = "22",
doi = "10.3233/JPD-2012-012095",
language = "English (US)",
volume = "2",
pages = "215--223",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease

T2 - Study design and rationale

AU - Charles, David

AU - Tolleson, Christopher

AU - Davis, Thomas L.

AU - Gill, Chandler E.

AU - Molinari, Anna L.

AU - Bliton, Mark J.

AU - Tramontana, Michael G.

AU - Salomon, Ronald M.

AU - Kao, Chris

AU - Wang, Lily

AU - Hedera, Peter

AU - Phibbs, Fenna T.

AU - Neimat, Joseph S.

AU - Konrad, Peter E.

PY - 2012/10/22

Y1 - 2012/10/22

N2 - Background: Deep brain stimulation provides significant symptomatic benefit for people with advanced Parkinson's disease whose symptoms are no longer adequately controlled with medication. Preliminary evidence suggests that subthalamic nucleus stimulation may also be efficacious in early Parkinson's disease, and results of animal studies suggest that it may spare dopaminergic neurons in the substantia nigra. Objective: We report the methodology and design of a novel Phase I clinical trial testing the safety and tolerability of deep brain stimulation in early Parkinson's disease and discuss previous failed attempts at neuroprotection. Methods: We recently conducted a prospective, randomized, parallel-group, single-blind pilot clinical trial of deep brain stimulation in early Parkinson's disease. Subjects were randomized to receive either optimal drug therapy or deep brain stimulation plus optimal drug therapy. Follow-up visits occurred every six months for a period of two years and included week-long therapy washouts. Results: Thirty subjects with Hoehn & Yahr Stage II idiopathic Parkinson's disease were enrolled over a period of 32 months. Twenty-nine subjects completed all follow-up visits; one patient in the optimal drug therapy group withdrew from the study after baseline. Baseline characteristics for all thirty patients were not significantly different. Conclusions: This study demonstrates that it is possible to recruit and retain subjects in a clinical trial testing deep brain stimulation in early Parkinson's disease. The results of this trial will be used to support the design of a Phase III, multicenter trial investigating the efficacy of deep brain stimulation in early Parkinson's disease.

AB - Background: Deep brain stimulation provides significant symptomatic benefit for people with advanced Parkinson's disease whose symptoms are no longer adequately controlled with medication. Preliminary evidence suggests that subthalamic nucleus stimulation may also be efficacious in early Parkinson's disease, and results of animal studies suggest that it may spare dopaminergic neurons in the substantia nigra. Objective: We report the methodology and design of a novel Phase I clinical trial testing the safety and tolerability of deep brain stimulation in early Parkinson's disease and discuss previous failed attempts at neuroprotection. Methods: We recently conducted a prospective, randomized, parallel-group, single-blind pilot clinical trial of deep brain stimulation in early Parkinson's disease. Subjects were randomized to receive either optimal drug therapy or deep brain stimulation plus optimal drug therapy. Follow-up visits occurred every six months for a period of two years and included week-long therapy washouts. Results: Thirty subjects with Hoehn & Yahr Stage II idiopathic Parkinson's disease were enrolled over a period of 32 months. Twenty-nine subjects completed all follow-up visits; one patient in the optimal drug therapy group withdrew from the study after baseline. Baseline characteristics for all thirty patients were not significantly different. Conclusions: This study demonstrates that it is possible to recruit and retain subjects in a clinical trial testing deep brain stimulation in early Parkinson's disease. The results of this trial will be used to support the design of a Phase III, multicenter trial investigating the efficacy of deep brain stimulation in early Parkinson's disease.

KW - deep brain stimulation

KW - Parkinson's disease

KW - research design

KW - subthalamic nucleus

UR - http://www.scopus.com/inward/record.url?scp=84867528835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867528835&partnerID=8YFLogxK

U2 - 10.3233/JPD-2012-012095

DO - 10.3233/JPD-2012-012095

M3 - Article

C2 - 23938229

AN - SCOPUS:84867528835

VL - 2

SP - 215

EP - 223

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 3

ER -